EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019–2023

Nai-Si Huang iD, Jia-Ying Chen, Wen-Jun Wei, Jia-Qian Hu, Yun-Jun Wang, Wan-Lin Liu, Qing Guan, Tuan-Qi Sun, Yu-Long Wang iD, Jun Xiang, Qing-Hai Ji, Dong-Mei Ji und 1 weitere

European Thyroid Journal · 01.12.2025 · 14 (6)

DOI: 10.1530/etj-24-0371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Thyroid Journal, online erschienen am 17.10.2025. Verfasst von Nai-Si Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Precision Medicine, Thyroid Carcinoma, Anaplastic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Anti-Cancer Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are both rare and aggressive thyroid cancers. Advances in targeted therapy and immunotherapy have changed treatment strategies and improved prognosis in these patients.

Methods

This single-center cohort study included patients diagnosed with locally advanced or metastatic PDTC/ATC at Fudan University Shanghai Cancer Center (FUSCC) between 2019 and 2023. Patients were either enrolled in clinical trials or received treatment based on clinical guidelines and expert consensus. Gene testing was conducted using next-generation sequencing of clinical samples.

Results

95 patients were analyzed (PDTC = 34, ATC = 61). Median overall survival (OS) was 19.7 months for PDTC and 9.5 months for ATC (P = 0.478). Among 82 patients who underwent gene testing, the most frequent gene alterations in PDTC were BRAF (50.0%), TERT promoter (39.3%), and TP53 (25.0%) mutations; in ATC, they were TERT promoter (55.6%), BRAF (42.6%), and TP53 (25.9%) mutations. Compared with ATC patients, PDTC patients were more likely to receive best supportive care and less likely to be enrolled in clinical trials or treated with PD-1 inhibitors. The 1-year OS rates for PDTC/ATC patients receiving neoadjuvant therapy + surgery, systemic treatment, and supportive care only were 83.3, 51.2, and 5.7%, respectively (P < 0.001). After adjusting for covariates, neoadjuvant therapy + surgery (hazard ratio = 0.216, 95% confidence interval: 0.647–0.718, P = 0.012) was an independent predictor of superior OS.

Conclusion

Despite the generally poor prognosis, aggressive treatment, particularly neoadjuvant therapy, has been shown to improve survival. Personalized treatment is crucial for optimizing treatment strategies for PDTC/ATC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsPrecision MedicineThyroid Carcinoma, AnaplasticHumansMaleFemaleMiddle AgedAgedAdultMutationAged, 80 and overProto-Oncogene Proteins B-rafTelomeraseCohort StudiesPrognosis

Stichwörter der Autor:innen

anaplastic thyroid cancerneoadjuvant therapypersonalized treatmentpoorly differentiated thyroid cancersurvival

Substanzen

Proto-Oncogene Proteins B-rafTERT protein, humanTelomeraseBRAF protein, human

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

ORCID-Profile: Nai-Si Huang, Yu-Long Wang, Yu Wang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Anti-Cancer Association
  • Shanghai Shen-kang Hospital Development Center

Zitieren

APA

Huang, N. S., Chen, J. Y., Wei, W. J., Hu, J. Q., Wang, Y. J., Liu, W. L., Guan, Q., Sun, T. Q., Wang, Y. L., Xiang, J., Ji, Q. H., Ji, D. M., & Wang, Y. (2025). Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019–2023. European Thyroid Journal, 14(6). https://doi.org/10.1530/etj-24-0371

Vancouver

Huang NS, Chen JY, Wei WJ, Hu JQ, Wang YJ, Liu WL, et al. Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019–2023. European Thyroid Journal. 2025;14(6). doi:10.1530/etj-24-0371

BibTeX
@article{Huang2025,
  author = {Huang, Nai-Si and Chen, Jia-Ying and Wei, Wen-Jun and Hu, Jia-Qian and Wang, Yun-Jun and Liu, Wan-Lin and Guan, Qing and Sun, Tuan-Qi and Wang, Yu-Long and Xiang, Jun and Ji, Qing-Hai and Ji, Dong-Mei and Wang, Yu},
  title = {Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019–2023},
  journal = {European Thyroid Journal},
  year = {2025},
  volume = {14},
  number = {6},
  doi = {10.1530/etj-24-0371}
}
Kostenlos starten →